U.S. health regulators paused Eli Lilly's coronavirus treatment trials, but experts aren't worried


A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
Federal health regulators paused enrollment in trials of Eli Lilly's coronavirus antibody treatment on Tuesday "out of an abundance of caution."
Officials did not explain why the pause was recommended, but a spokesperson for the company indicated it was "supportive of the decision" by an independent data safety monitoring board. Dr. Carlos del Rio, an infectious diseases expert at Emory University School of Medicine, told NBC News that "pauses are not infrequent in a clinical trial," especially one as "truncated" as the COVID-19 treatment development process.
The decision comes after Johnson & Johnson announced Monday night it paused its coronavirus vaccine trial. One of its volunteers came down with an "unexplained illness," though it's unclear if that illness had anything to do with the vaccine.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Last week, Eli Lilly said it would soon request emergency authorization for another antibody treatment it had developed. The treatment paused Tuesday was determined to reduce patients' COVID-19 viral load and help them avoid hospitalization. It's similar to the treatment from Regeneron given to President Trump.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
Kathryn is a graduate of Syracuse University, with degrees in magazine journalism and information technology, along with hours to earn another degree after working at SU's independent paper The Daily Orange. She's currently recovering from a horse addiction while living in New York City, and likes to share her extremely dry sense of humor on Twitter.
-
FDA to re-evaluate effectiveness of common nasal congestion ingredient
Speed Read
By Justin Klawans Published
-
A flesh-eating bacteria is growing in numbers due to climate change
Speed Read
By Devika Rao Published
-
CDC recommends new RSV vaccine for infants under 8 months
Speed Read
By Devika Rao Published
-
U.S. health agency advises easing federal marijuana restrictions
Speed Read
By Peter Weber Published
-
Medicare drug price negotiations start with 1st 10 drugs, pharmaceutical industry lawsuits
Speed Read
By Peter Weber Published
-
Air pollution may be increasing antibiotic resistance, new research suggests
Speed Read
By Devika Rao Published
-
Tick bites could cause an allergy to red meat, CDC says
Speed Read
By Devika Rao Published
-
The danger of drinking too much water
Speed Read
By Devika Rao Published